Published in Nat Rev Neurol on March 13, 2012
Rabbit genome analysis reveals a polygenic basis for phenotypic change during domestication. Science (2014) 1.96
Tourette syndrome and other tic disorders in childhood, adolescence and adulthood. Dtsch Arztebl Int (2012) 1.72
The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol (2014) 1.04
Personalized genomic disease risk of volunteers. Proc Natl Acad Sci U S A (2013) 0.99
Common and rare alleles of the serotonin transporter gene, SLC6A4, associated with Tourette's disorder. Mov Disord (2013) 0.83
Selective activation of D1 dopamine receptors impairs sensorimotor gating in Long-Evans rats. Br J Pharmacol (2015) 0.82
Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits. Curr Top Dev Biol (2014) 0.81
Immune-mediated animal models of Tourette syndrome. Neurosci Biobehav Rev (2013) 0.81
Recent Advances in Understanding and Managing Tourette Syndrome. F1000Res (2016) 0.81
The Tourette International Collaborative Genetics (TIC Genetics) study, finding the genes causing Tourette syndrome: objectives and methods. Eur Child Adolesc Psychiatry (2014) 0.80
Tourette syndrome and comorbid ADHD: causes and consequences. Eur J Pediatr (2014) 0.79
The implication of neuroactive steroids in Tourette's syndrome pathogenesis: A role for 5α-reductase? J Neuroendocrinol (2013) 0.79
Correlations of gene expression with ratings of inattention and hyperactivity/impulsivity in Tourette syndrome: a pilot study. BMC Med Genomics (2012) 0.79
Involvement of astrocyte metabolic coupling in Tourette syndrome pathogenesis. Eur J Hum Genet (2015) 0.78
Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord (2014) 0.78
Involvement of tryptophan hydroxylase 2 gene polymorphisms in susceptibility to tic disorder in Chinese Han population. Behav Brain Funct (2013) 0.77
The Genetic Etiology of Tourette Syndrome: Large-Scale Collaborative Efforts on the Precipice of Discovery. Front Neurosci (2016) 0.77
Prenatal Maternal Smoking and Tourette Syndrome: A Nationwide Register Study. Child Psychiatry Hum Dev (2016) 0.77
Social disinhibition is a heritable subphenotype of tics in Tourette syndrome. Neurology (2016) 0.76
Tourette Syndrome and Comorbid Neuropsychiatric Conditions. Curr Dev Disord Rep (2016) 0.75
Association of ADORA1 rs2228079 and ADORA2A rs5751876 Polymorphisms with Gilles de la Tourette Syndrome in the Polish Population. PLoS One (2015) 0.75
Pediatric Autoimmune Disorders Associated with Streptococcal Infections and Tourette's Syndrome in Preclinical Studies. Front Neurosci (2016) 0.75
Strong association of de novo copy number mutations with autism. Science (2007) 27.84
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet (2003) 15.31
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron (1999) 3.52
Histamine in the nervous system. Physiol Rev (2008) 3.47
L-histidine decarboxylase and Tourette's syndrome. N Engl J Med (2010) 2.92
Tourette's syndrome. N Engl J Med (2001) 2.78
Tourette's syndrome. Lancet (2002) 2.56
The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. N Engl J Med (1986) 2.30
CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics (2003) 2.29
Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci U S A (2010) 2.10
Tourette syndrome, associated conditions and the complexities of treatment. Brain (2000) 2.09
A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature (2010) 2.00
Tourette syndrome is associated with recurrent exonic copy number variants. Neurology (2010) 1.99
Familial deletion within NLGN4 associated with autism and Tourette syndrome. Eur J Hum Genet (2008) 1.97
The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res (2008) 1.88
Tourette syndrome: evolving concepts. Mov Disord (2011) 1.84
Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum Mol Genet (2006) 1.84
Prevalence of diagnosed Tourette syndrome in persons aged 6-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep (2009) 1.80
A twin study of Tourette syndrome. Arch Gen Psychiatry (1985) 1.65
Uncovering the total heritability explained by all true susceptibility variants in a genome-wide association study. Genet Epidemiol (2011) 1.61
Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. Am J Hum Genet (2007) 1.60
A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J Neurosci (2009) 1.59
Disruption of CNTNAP2 and additional structural genome changes in a boy with speech delay and autism spectrum disorder. Neurogenetics (2009) 1.58
Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. Mol Cell Neurosci (2003) 1.57
The genetics of child psychiatric disorders: focus on autism and Tourette syndrome. Neuron (2010) 1.57
Novel splice isoforms for NLGN3 and NLGN4 with possible implications in autism. J Med Genet (2006) 1.54
Absence of coding mutations in the X-linked genes neuroligin 3 and neuroligin 4 in individuals with autism from the IMGSAC collection. Am J Med Genet B Neuropsychiatr Genet (2006) 1.53
A family study of Gilles de la Tourette syndrome. Am J Hum Genet (1991) 1.49
Peek-a-boo fragile site at 16d associated with Tourette syndrome, bipolar disorder, autistic disorder, and mental retardation. Am J Med Genet (2000) 1.47
The genetics of Tourette syndrome: a review. J Psychosom Res (2009) 1.46
Slitrk1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities. Mol Psychiatry (2008) 1.41
Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome. Am J Hum Genet (2001) 1.37
Tourette's syndrome: from behaviour to biology. Lancet Neurol (2005) 1.36
A complete genome screen in sib pairs affected by Gilles de la Tourette syndrome. The Tourette Syndrome Association International Consortium for Genetics. Am J Hum Genet (1999) 1.35
Latent class analysis of gilles de la tourette syndrome using comorbidities: clinical and genetic implications. Biol Psychiatry (2008) 1.34
Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry (2010) 1.33
Disruption of the CNTNAP2 gene in a t(7;15) translocation family without symptoms of Gilles de la Tourette syndrome. Eur J Hum Genet (2007) 1.33
Clinical practice. Tourette's Syndrome. N Engl J Med (2010) 1.31
Relationship of birth weight to the phenotypic expression of Gilles de la Tourette's syndrome in monozygotic twins. Neurology (1992) 1.31
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand (2006) 1.26
Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet (1996) 1.24
Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther (2010) 1.23
Functional SLITRK1 var321, varCDfs and SLC6A4 G56A variants and susceptibility to obsessive-compulsive disorder. Mol Psychiatry (2006) 1.23
Familial pattern and transmission of Gilles de la Tourette syndrome and multiple tics. Arch Gen Psychiatry (1981) 1.21
A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice. Biol Reprod (2007) 1.20
Treatment of hyperkinetic movement disorders. Lancet Neurol (2009) 1.19
Tourette syndrome in a pedigree with a 7;18 translocation: identification of a YAC spanning the translocation breakpoint at 18q22.3. Am J Hum Genet (1996) 1.16
Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet (2000) 1.15
Genetic analysis of Tourette syndrome suggesting major gene effect. Am J Hum Genet (1981) 1.14
Lack of association between SLITRK1var321 and Tourette syndrome in a large family-based sample. Neurology (2008) 1.14
Recent advances in Tourette syndrome. Curr Opin Neurol (2011) 1.13
Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. Am J Hum Genet (2002) 1.13
Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J Neurochem (2002) 1.12
Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr (2005) 1.10
Malignant Tourette syndrome. Mov Disord (2007) 1.07
SLITRK1 binds 14-3-3 and regulates neurite outgrowth in a phosphorylation-dependent manner. Biol Psychiatry (2009) 1.05
Autosomal dominant gene transmission in a large kindred with Gilles de la Tourette syndrome. Br J Psychiatry (1992) 1.05
Slitrks as emerging candidate genes involved in neuropsychiatric disorders. Trends Neurosci (2011) 1.04
Developmentally regulated and evolutionarily conserved expression of SLITRK1 in brain circuits implicated in Tourette syndrome. J Comp Neurol (2009) 1.04
Significant linkage for Tourette syndrome in a large French Canadian family. Am J Hum Genet (2000) 1.04
Association of the Slit and Trk-like 1 gene in Taiwanese patients with Tourette syndrome. Pediatr Neurol (2007) 1.03
Bilineal transmission in Tourette's syndrome families. Neurology (1994) 1.03
Linkage analysis of ordinal traits for pedigree data. Proc Natl Acad Sci U S A (2004) 1.02
Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. Proc Natl Acad Sci U S A (2003) 1.01
Mature DIABLO/Smac is produced by the IMP protease complex on the mitochondrial inner membrane. Mol Biol Cell (2005) 1.01
Gene location in Tourette syndrome. Lancet (1987) 0.99
LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand (2011) 0.99
The genetics of Tourette disorder. Curr Opin Genet Dev (2011) 0.99
Indications of linkage and association of Gilles de la Tourette syndrome in two independent family samples: 17q25 is a putative susceptibility region. Am J Hum Genet (2004) 0.98
Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann N Y Acad Sci (2001) 0.97
Family-based genetic association study of DLGAP3 in Tourette Syndrome. Am J Med Genet B Neuropsychiatr Genet (2010) 0.97
Sequence analysis of the complete SLITRK1 gene in Austrian patients with Tourette's disorder. Psychiatr Genet (2008) 0.97
Additional support for the association of SLITRK1 var321 and Tourette syndrome. Mol Psychiatry (2010) 0.96
Further evidence for linkage of Gilles de la Tourette syndrome (GTS) susceptibility loci on chromosomes 2p11, 8q22 and 11q23-24 in South African Afrikaners. Am J Med Genet (2001) 0.96
Molecular and genomic studies of IMMP2L and mutation screening in autism and Tourette syndrome. Mol Genet Genomics (2006) 0.95
Genome scan for linkage to Gilles de la Tourette syndrome. Am J Med Genet (1999) 0.95
Translocation breakpoint at 7q31 associated with tics: further evidence for IMMP2L as a candidate gene for Tourette syndrome. Eur J Hum Genet (2011) 0.95
Association of SLITRK1 to Gilles de la Tourette Syndrome. Am J Med Genet B Neuropsychiatr Genet (2009) 0.95
Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res (1996) 0.95
Exome sequencing of a pedigree with Tourette syndrome or chronic tic disorder. Ann Neurol (2011) 0.94
Genetic and clinical analysis of a large Dutch Gilles de la Tourette family. Mol Psychiatry (2006) 0.94
Identification of genetic markers associated with Gilles de la Tourette syndrome in an Afrikaner population. Am J Hum Genet (1998) 0.94
Deficiency in the inner mitochondrial membrane peptidase 2-like (Immp21) gene increases ischemic brain damage and impairs mitochondrial function. Neurobiol Dis (2011) 0.93
Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population. Mol Psychiatry (2004) 0.92
Candidate region for Gilles de la Tourette syndrome at 7q31. Am J Med Genet (2001) 0.91
Bilineal transmission and phenotypic variation of Tourette's disorder in a large pedigree. J Am Acad Child Adolesc Psychiatry (1996) 0.91
Non-random X chromosome inactivation in an affected twin in a monozygotic twin pair discordant for Wiedemann-Beckwith syndrome. Am J Med Genet (1995) 0.90
Tourette syndrome and klippel-feil anomaly in a child with chromosome 22q11 duplication. Case Rep Med (2009) 0.90
Dopa-responsive dystonia and Tourette syndrome in a large Danish family. Arch Neurol (2003) 0.89
Tourette syndrome and other tic disorders. Handb Clin Neurol (2011) 0.89
Genome scan of Tourette syndrome in a single large pedigree shows some support for linkage to regions of chromosomes 5, 10 and 13. Psychiatr Genet (2004) 0.88
Association of intronic variants of the BTBD9 gene with Tourette syndrome. Arch Neurol (2009) 0.88
A large Italian family with Gilles de la Tourette syndrome: clinical study and analysis of the SLITRK1 gene. Mov Disord (2007) 0.87
A patient with both Gilles de la Tourette's syndrome and chromosome 22q11 deletion syndrome: clue to the genetics of Gilles de la Tourette's syndrome? J Psychosom Res (2006) 0.87
Mutation screening of the HDC gene in Chinese Han patients with Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet (2011) 0.86
Microarray analysis in children with developmental disorder or epilepsy. Pediatr Neurol (2010) 0.86
LRRK2 mutations and Parkinsonism. Lancet (2005) 0.86
Occurrence of tics in Asperger's syndrome and autistic disorder. J Child Neurol (2000) 0.85
Candidate locus for Gilles de la Tourette syndrome/obsessive compulsive disorder/chronic tic disorder at 18q22. Am J Med Genet A (2004) 0.84
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol (2006) 3.07
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia (2015) 2.17
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol (2005) 1.93
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2011) 1.58
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Coexistence of different genotypes in the same bat and serological characterization of Rousettus bat coronavirus HKU9 belonging to a novel Betacoronavirus subgroup. J Virol (2010) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals (2011) 1.30
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol (2006) 1.29
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain (2006) 1.29
Novel avian-origin human influenza A(H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis (2013) 1.28
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (2013) 1.27
Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol (2002) 1.26
Runner's dystonia. J Neurol Sci (2006) 1.24
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord (2004) 1.24
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord (2006) 1.23
Iron dysregulation in movement disorders. Neurobiol Dis (2012) 1.22
Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res (Hoboken) (2010) 1.21
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A (2006) 1.20
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol (2013) 1.20
An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) (2013) 1.20
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20
Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord (2011) 1.18
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology (2002) 1.18
Reliability of a new scale for essential tremor. Mov Disord (2012) 1.17
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord (2007) 1.17
Secondary paroxysmal dyskinesias. Mov Disord (2002) 1.17
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord (2010) 1.17
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother (2006) 1.16
Movement disorders in autoimmune diseases. Mov Disord (2012) 1.16
Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage (2009) 1.16
The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry (2013) 1.15
Preclinical biomarkers of Parkinson disease. Arch Neurol (2011) 1.14
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol (2008) 1.12
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology (2014) 1.11
Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci (2008) 1.10
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol (2005) 1.10
Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol (2002) 1.10
Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord (2010) 1.09